Dexamethasone cipecilate dry powder

Drug Profile

Dexamethasone cipecilate dry powder

Alternative Names: Erizas; NS-126; NS-126C

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Developer Nippon Shinyaku; Yooyoung Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Glucocorticoids; Pregnadienetriols
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis
  • Discontinued Asthma

Most Recent Events

  • 01 Feb 2016 Launched for Allergic rhinitis in South Korea (Intranasal)
  • 03 Dec 2015 Preregistration for Allergic rhinitis in South Korea (Intranasal) prior to December 2015 (Yooyoung Pharmaceutical's pipeline, December 2015)
  • 06 Mar 2014 Discontinued - Phase-II for Asthma in Japan (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top